UNSPSC 51273929: Dextrose/lidocaine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.

UNSPSC 51273929 Dextrose/lidocaine (Commodity) tracks pharmaceutical products and related medical supplies procured by state and local health authorities, though recent solicitations under this code show activity concentrated in naloxone, drug deactivation systems, and broader generic pharmaceutical procurement rather than dextrose or lidocaine specifically. State and local governments use this code to source emergency medications, opioid-reversal agents, and pharmaceutical inventories through competitive bidding and cooperative purchasing vehicles. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across member jurisdictions. Seminole County, Florida and the Texas Health and Human Services Commission represent recent buyers; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by Minnesota's Department of Administration extends procurement reach across multiple states including Oregon.

Recent activity spans Florida, Texas, and the Upper Midwest through cooperative arrangements. Seminole County released IFB60459723LAS on June 30, 2026 (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, requiring bidders to include shipping costs and comply with E-Verify and drug-free workplace certifications; the contract carries a two-year initial term with one-year renewal option and potential FEMA funding. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities on direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager and group purchasing organization channels, signaling state interest in alternative pharmaceutical distribution models. MMCAP issued an RFP (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with awards effective July 1, 2026; vendors must certify cGMP and Drug Supply Chain Security Act compliance, maintain relationships with at least two wholesalers, and accept a 3 percent administrative fee. Pricing and product information submission required Excel-to-CSV conversion through MMCAP's ePro system, with insurance requirements including $5 million commercial general liability and $2 million network security liability per occurrence.